BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Yin XY, Lü MD, Liang LJ, Lai JM, Li DM, Kuang M. Systemic chemo-immunotherapy for advanced-stage hepatocellular carcinoma. World J Gastroenterol 2005; 11(16): 2526-2529 [PMID: 15832431 DOI: 10.3748/wjg.v11.i16.2526]
URL: https://www.wjgnet.com/1007-9327/full/v11/i16/2526.htm
Number Citing Articles
1
Tim F. Greten, Michael P. Manns, Firouzeh Korangy. Immunotherapy of hepatocellular carcinomaJournal of Hepatology 2006; 45(6): 868 doi: 10.1016/j.jhep.2006.09.004
2
Qi-Da Hu, Wei Chen, Tian-Lian Yan, Tao Ma, Cong-Lin Chen, Chao Liang, Qi Zhang, Xue-Feng Xia, Hao Liu, Xiao Zhi, Xiao-Xiao Zheng, Xue-Li Bai, Xia-Zhen Yu, Ting-Bo Liang. NSC 74859 enhances doxorubicin cytotoxicity via inhibition of epithelial–mesenchymal transition in hepatocellular carcinoma cellsCancer Letters 2012; 325(2): 207 doi: 10.1016/j.canlet.2012.07.003
3
Nobuhiro Tsuchiya, Yu Sawada, Itaru Endo, Yasushi Uemura, Tetsuya Nakatsura. Potentiality of immunotherapy against hepatocellular carcinomaWorld Journal of Gastroenterology 2015; 21(36): 10314-10326 doi: 10.3748/wjg.v21.i36.10314
4
Li‐Jian Liang, Wen‐Jie Hu, Xiao‐Yu Yin, Qi Zhou, Bao‐Gang Peng, Dong‐Ming Li, Ming‐De Lu. Adjuvant Intraportal Venous Chemotherapy for Patients with Hepatocellular Carcinoma and Portal Vein Tumor Thrombi Following Hepatectomy Plus Portal ThrombectomyWorld Journal of Surgery 2008; 32(4): 627 doi: 10.1007/s00268-007-9364-0
5
Terry Lichtor, Alessandra Spagnolo, Roberta P. Glick, Douglas L. Feinstein, Dipak Panigrahy. PPAR‐γ Thiazolidinedione Agonists and Immunotherapy in the Treatment of Brain TumorsPPAR Research 2008; 2008(1) doi: 10.1155/2008/547470
6
Ahmed O. Kaseb, Junichi Shindoh, Yehuda Z. Patt, Robert E. Roses, Giuseppe Zimmitti, Richard D. Lozano, Manal M. Hassan, Hesham M. Hassabo, Steven A. Curley, Thomas A. Aloia, James L. Abbruzzese, Jean‐Nicolas Vauthey. Modified cisplatin/interferon α‐2b/doxorubicin/5‐fluorouracil (PIAF) chemotherapy in patients with no hepatitis or cirrhosis is associated with improved response rate, resectability, and survival of initially unresectable hepatocellular carcinomaCancer 2013; 119(18): 3334 doi: 10.1002/cncr.28209
7
Zhang Chunhu, Hu Suiyu, Cao Meiqun, Xiao Guilin, Li Yunhui. Antiproliferative and apoptotic effects of paeonol on human hepatocellular carcinoma cellsAnti-Cancer Drugs 2008; 19(4): 401 doi: 10.1097/CAD.0b013e3282f7f4eb
8
Qiang Gao, Yinghong Shi, Xiaoying Wang, Jian Zhou, Shuangjian Qiu, Jia Fan. Translational medicine in hepatocellular carcinomaFrontiers of Medicine 2012; 6(2): 122 doi: 10.1007/s11684-012-0193-7
9
Bazarragchaa Damdinsuren, Hiroaki Nagano, Morito Monden. Combined intra‐arterial 5‐fluorouracil and subcutaneous interferon‐alpha therapy for highly advanced hepatocellular carcinomaHepatology Research 2007; 37(s2) doi: 10.1111/j.1872-034X.2007.00191.x
10
Alessandra Spagnolo, Roberta P. Glick, Henry Lin, Edward P. Cohen, Douglas L. Feinstein, Terry Lichtor. Prolonged survival of mice with established intracerebral glioma receiving combined treatment with peroxisome proliferator-activated receptor–γ thiazolidinedione agonists and interleukin-2–secreting syngeneic/allogeneic fibroblastsJournal of Neurosurgery 2007; 106(2): 299 doi: 10.3171/jns.2007.106.2.299